Menu and flexibility with QIAscreen HPV PCR Test

Contact a QIAscreen expert

A history of QIAGEN’s commitment to cervical cancer screening

QIAGEN has been committed to women’s health diagnostics for over 20 years. In this time, QIAGEN has built a comprehensive range of cervical cancer screening solutions to reach as many women as possible. We understand that our customers need different solutions for HPV testing based on their size, setting, and budget.

digene HC2 Test

  • The 1st FDA-approved HPV test
  • The gold standard for sensitive, early detection of high-risk HPV
  • Evaluated worldwide in clinical studies with >1 million women

careHPV Test

  • One of the only molecular diagnostics for low-resource settings
  • Part of the the World Health Organization’s list of prequalified in vitro diagnostics

QIAsure Test

  • A follow-up test for HPV-positive patients
  • Accurately differentiates patients’ risk of developing cervical cancer

QIAscreen Test

  • A new solution with diverse menu options and a flexible workflow
  • Unique targeting and validated by Meijer guidelines

The future of cervical cancer screening with QIAscreen

QIAscreen provides a menu of applications and flexibility in sample input options for HPV testing. Watch the video to find out more about the new QIAscreen test.

Resources for download

Introducing QIAscreen, a new HPV PCR screening solution.

 

The QIAscreen HPV PCR Test is an in vitro real-time PCR-based assay for the qualitative detection of human papillomavirus (HPV) DNA of 15 (likely) (1) high-risk HPV genotypes.

QIAscreen can bolster your Rotor-Gene Q workflow, providing a menu of applications on one instrument.

QIAscreen rounds out QIAGEN’s family of PCR-based women’s health tests on the Rotor-Gene Q instrument, which include tests for C. trachomatis, N. gonorrhoeae, and T. vaginalis.  Labs can conduct a panel of women’s health tests in a more streamlined and resourceful manner to provide comprehensive insights for clinicians and patients.

In addition, QIAscreen has several unique features:

  • Total HR-HPV Detection

    QIAscreen detects 15 HPV types: 14 identified high-risk HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) and 1 likely high-risk HPV type (67).

  • Unique HPV targeting

    QIAscreen is an HPV PCR test targeting the E7 gene. The viral E6/E7 region is invariably retained in integrated viral genomes in cervical cancers (2).

  • Compatible with self sampling

    QIAscreen was validated for many sample types, including physician-taken samplings and self sampling (i.e. lavage and brush)

  • Flexible workflow

    QIAscreen’s open-ended sample extraction works with all common methods, such as the QIAsymphony system.

References

1) International Agency for Research on Cancer. (2009). A review of human carcinogens. Part B: Biological Agents. Monographs 100B.

2) Snijders, P.J., Steenbergen, R.D., Heideman, D.A., Meijer, C.J. (2006) HPV-mediated cervical carcinogenesis: concepts and clinical implications. J. Pathol. 208, 152.

3) QIAscreen HPV PCR Test Instructions for Use. QIAGEN, 2018.

 

The QIAscreen HPV PCR Test is intended for in vitro diagnostic use in Europe. Self-screen B.V. is the legal manufacturer of the QIAscreen HPV PCR Test.

Social Sharing